Health
FDA Approves Infilbray as First Treatment for Neurological Symptoms of Type 3 Gaucher Disease
Sanofi's Infilbray becomes the first FDA-approved therapy targeting the neurological decline in Gaucher disease type 3, offering hope for a rare patient population.